1. Home
  2. RETO vs KPRX Comparison

RETO vs KPRX Comparison

Compare RETO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RETO

ReTo Eco-Solutions Inc.

HOLD

Current Price

$2.68

Market Cap

10.0M

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.68

Market Cap

10.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RETO
KPRX
Founded
1999
1998
Country
China
United States
Employees
N/A
13
Industry
Multi-Sector Companies
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
10.7M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
RETO
KPRX
Price
$2.68
$2.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
52.9K
23.2K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.76
52 Week High
$4.66
$3.29

Technical Indicators

Market Signals
Indicator
RETO
KPRX
Relative Strength Index (RSI) 58.54 53.22
Support Level $2.49 $2.47
Resistance Level $2.80 $2.72
Average True Range (ATR) 0.18 0.11
MACD -0.06 0.00
Stochastic Oscillator 59.32 65.63

Price Performance

Historical Comparison
RETO
KPRX

About RETO ReTo Eco-Solutions Inc.

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: